Clinical Operations & Patient Safety · Healthcare & Life Sciences
Should you build or buy Clinical Surveillance & Deterioration Prediction Platform?
A clinical surveillance and deterioration prediction platform continuously monitors structured vitals, labs, and nursing assessment data from the EHR to identify patients at elevated risk for sepsis, respiratory failure, or rapid deterioration — generating alerts that trigger timely clinical intervention. These platforms combine rule-based triggers with machine learning models, and many are deployed as FDA-cleared Software as a Medical Device.
The build-vs-buy decision for Clinical Surveillance & Deterioration Prediction platforms turns on whether your institution has the data science capacity to train and validate models that outperform vendor offerings on your specific patient population, and whether FDA clearance as a medical device is a regulatory obstacle your team can navigate or a barrier that makes buying the more practical path; the specifics decide it.
Build it, buy it, or bridge?
When building makes sense
Building a deterioration prediction platform is genuinely feasible for the right institution. UCSF, University of Michigan, and other large academic medical centers have published production self-built deterioration models trained on their Epic and Cerner data — the ML problem itself is tractable. Structured vitals and labs in standardized FHIR/HL7 formats are well-understood inputs, and the model development path is documented. The build case gets serious when you have a mature data science team, owned EHR data, and a patient population with characteristics that make generic vendor models a poor fit — specific case mixes, unusual payer distributions, or clinical specialties where commercial models haven't been validated. The honest obstacle is regulatory, not technical. Deploying the model clinically as a deterioration alert triggers FDA SaMD oversight, and getting and maintaining clearance is a multi-year commitment. Institutions that have built here typically run internal models alongside vendor platforms, using the internal version for research and quality improvement while the FDA-cleared vendor tool handles the clinical alert workflow.
When buying makes sense
Buying earns its keep for any hospital that needs functioning deterioration alerts without a clinical informatics team capable of building, validating, and maintaining FDA-cleared models. That is the majority of health systems. Vendors like CLEW Medical, AgileMD, and Prenosis (via Roche) carry the regulatory burden — FDA clearance, ongoing model revalidation, and clinical evidence documentation — as part of the product. For community hospitals and mid-size IDNs, the choice isn't between a vendor model and a better homegrown model; it's between a vendor model and nothing, because the regulatory and staffing requirements for self-deployment are out of reach. Even for better-resourced organizations, the practical advantage of buying is speed: a configured vendor platform can be generating clinically actionable alerts in months, while the internal build path takes years before any patient-facing deployment.
The desk read
Large academic medical centers like UCSF and University of Michigan have published production self-built deterioration models trained on their Epic and Cerner data, so the ML itself isn't the barrier. Structured vitals and lab data flowing through FHIR/HL7 feeds is a tractable machine learning problem, and the model math is well-documented. The build case gets serious when you have a mature data science team, owned EHR data, and the patience to build the alert management and clinical dashboard layer on top.
What stops most organizations isn't the algorithm, it's FDA clearance. Deploying a deterioration prediction tool as clinical decision support triggers Software as a Medical Device (SaMD) regulation, and getting and maintaining that clearance is a real ongoing cost. Vendors like CLEW Medical, AgileMD, and Prenosis (via Roche) carry that regulatory burden as part of what you're paying for. The AI era is making the model itself cheaper to build; the regulatory envelope is what keeps this decision live and complicated.
Frequently asked
What is a Clinical Surveillance & Deterioration Prediction Platform?
A clinical surveillance and deterioration prediction platform continuously monitors structured vitals, labs, and nursing assessment data from the EHR to identify patients at elevated risk for sepsis, respiratory failure, or rapid deterioration. These platforms combine rule-based triggers with machine learning models, and many are deployed as FDA-cleared Software as a Medical Device.
When does building a Clinical Surveillance & Deterioration Prediction Platform make sense?
Building is feasible for large academic medical centers with mature data science teams and distinctive patient populations where vendor models underperform. The ML is tractable — UCSF and other AMCs have documented production self-builds — but FDA SaMD clearance is a multi-year regulatory commitment that limits who can realistically pursue this path.
When does buying a Clinical Surveillance & Deterioration Prediction Platform make sense?
Buying makes sense for any health system that needs clinically deployed deterioration alerts without the capacity to build, validate, and maintain an FDA-cleared model. Vendors carry the regulatory burden and ongoing model revalidation, which is the most practical path for the majority of hospitals.
What are the main Clinical Surveillance & Deterioration Prediction Platform vendors?
Representative vendors include CLEW Medical, care.ai Smart Care Facility Platform, AgileMD (eCART Clinical Deterioration Suite), Prenosis (Sepsis ImmunoScore, via Roche). B4 Pro scores the full set.
What is the FDA SaMD pathway, and why does it matter here?
Software as a Medical Device (SaMD) is FDA's classification for software that performs a medical function independently of a physical device — including clinical decision support tools that generate patient-specific alerts. Deterioration prediction platforms that provide actionable clinical recommendations typically require FDA clearance, which involves a multi-year validation and submission process. Vendors carry this clearance as part of their product; self-built tools deployed clinically must navigate it independently.